Why the study?
Do platelet GP IIIa PlA polymorphisms affect sensitivity to agonists and antiplatelet drugs in vitro?
Do platelet GP IIIa PlA polymorphisms affect sensitivity to agonists and antiplatelet drugs in vitro?
Answers are grounded in this paper and cite their sources.
In vitro studies show that Pl(A2)-positive platelets have a lower activation threshold and heterozygous platelets have increased sensitivity to antiplatelet drugs, which may have implications for in vivo thrombotic conditions.
Pl(A2)-positive platelets displayed a lower threshold for activation, and platelets heterozygous for Pl(A) alleles showed increased sensitivity to 2 antiplatelet drugs. These in vitro platelet studies may have relevance for in vivo thrombotic conditions.
No takes yet. Share an insight, caveat, or question.
Michelson et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: